Review top news and interview highlights from the week ending April 8, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The gene therapy ASC618 has received European and US designations and opinions that could help expedite development for hemophilia A.
The company will be cutting its workforce by 30% in order to extend its cash runway into 2023 as it awaits 2 key FDA decisions on betibeglogene autotemcel (beti-cel) and elivaldogene autotemcel (eli-cel).
The FDA has approved second-line axicabtagene ciloleucel as a treatment for adult patients with large B-cell lymphoma following frontline chemoimmunotherapy.
The investigational therapy leverages an advanced overnight nonviral gene delivery manufacturing process that may help it overcome existing treatment limitations.
Iovance Biotherapeutics has received positive feedback from the FDA regarding their proposed potency assay and cell co-culture assays for its upcoming Biologics License Application (BLA) for lifileucel (LN-144) for the potential treatment of metastatic melanoma.